Guided Therapeutics Inc. has announced preliminary findings from its FDA pivotal clinical trial evaluating the LuViva Advanced Cervical Scan, a device designed for rapid and painless cervical cancer detection using biophotonic technology. The initial results indicate that the current standard of care misses approximately 25% of early cervical precancer cases among women referred for biopsy following abnormal Pap and/or HPV results. The LuViva device aims to improve detection rates of these cases. The completed study enrolled approximately 480 subjects, with over 420 to be evaluated for efficacy, meeting FDA-reviewed protocol criteria. Final clinical results are expected to be filed with the FDA within the next 30 to 60 days. Results from the study have not yet been presented.